Search

Search Constraints

You searched for: Author/Creator Nanchen, David

Search Results

1. CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. (October 2021)

5. Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. (15th January 2020)

8. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. Issue 11 (9th November 2017)

9. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. (20th July 2020)

10. Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Issue 1 (March 2015)